Meeting
2023 ASCO Annual Meeting
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
Authors
Arthur Geraud
Gustave Roussy Institute, Villejuif, France
Arthur Geraud , David Combarel , Christian Funck-Brentano , Quentin Beaulien , Noel Zahr , Sophie Broutin , Christophe Massard , Benjamin Besse , Paul Gougis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Pharmacology/Pharmacodynamics/Pharmacogenetics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3091)
DOI
10.1200/JCO.2023.41.16_suppl.3091
Abstract #
3091
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2018 ASCO Annual Meeting
Duration of physician-industry relationships and prescribing changes in oncology.
First Author: Aaron Philip Mitchell
Poster
2018 Genitourinary Cancers Symposium
Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC).
First Author: Annalisa Guida